Tenaya Therapeutics has received fast track designation for a phase 1b clinical trial for MYBPC3 gene replacement therapy for hypertrophic cardiomyopathy (NCT05836259), utilizing an optimized AAV9 vector to package the full-length MYBPC3 gene. The gene discussed is MYBPC3; the disease is hypertrophic cardiomyopathy.